Down Syndrome – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Down Syndrome – Pipeline Review, H2 2019’, provides an overview of the Down Syndrome pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Down Syndrome and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Down Syndrome

– The report reviews pipeline therapeutics for Down Syndrome by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Down Syndrome therapeutics and enlists all their major and minor projects

– The report assesses Down Syndrome therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Down Syndrome”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Down Syndrome

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Down Syndrome pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AC Immune SA

Advanced Medical Projects

Aelis Farma SAS

Alzheon Inc

Amgen Inc

Annovis Bio Inc

Avanti Biosciences Inc

Balance Therapeutics Inc

Eisai Co Ltd

Elixirgen Therapeutics LLC

F. Hoffmann-La Roche Ltd

KinoPharma Inc

ManRos Therapeutics

NeuroCircuit Therapeutics Inc

NeuroNascent Inc

San Biotechnology Co Ltd”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Down Syndrome Overview

Down Syndrome Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Down Syndrome Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Down Syndrome Companies Involved in Therapeutics Development

AC Immune SA

Eisai Co Ltd

F. Hoffmann-La Roche Ltd

ManRos Therapeutics

NeuroNascent Inc

San Biotechnology Co Ltd

Down Syndrome Drug Profiles

ABI-02 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACI-24 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BAN-2401 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

D-217 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dosmir Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ZSCAN4 for Chromosomal Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KPO-1143 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

minocycline hydrochloride Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NNI-351 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentylenetetrazol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RO-4938581 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibit DYRK1A for Down Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules for Down Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DYRK1A for Alzheimer’s Disease and Down Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit OLIG2 for Down Syndrome Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Down Syndrome Dormant Projects

Down Syndrome Discontinued Products

Down Syndrome Product Development Milestones

Featured News & Press Releases

Aug 20, 2018: AC Immune announces important clinical milestones for ACI-24 vaccine in alzheimers disease and down syndrome

Sep 12, 2017: AC Immune Completes Recruitment For Low-Dose Cohort In World's First Clinical Trial For Anti-Abeta Vaccine Targeting Alzheimer's Disease-Like Characteristics In Individuals With Down Syndrome

Apr 05, 2016: AC Immune Announces Publication of Ground-breaking Scientific Publication on anti-Abeta Vaccine in Preclinical Model of Down Syndrome

Feb 05, 2015: Neuronascent Announces Expanded Patent Coverage in Russia for Its Down Syndrome Therapeutics

Feb 27, 2013: Roche Research Sheds Light On Improving Neurological Deficits In Mouse Model Of Down Syndrome

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Down Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Down Syndrome – Pipeline by AC Immune SA, H2 2019

Down Syndrome – Pipeline by Advanced Medical Projects, H2 2019

Down Syndrome – Pipeline by Aelis Farma SAS, H2 2019

Down Syndrome – Pipeline by Alzheon Inc, H2 2019

Down Syndrome – Pipeline by Amgen Inc, H2 2019

Down Syndrome – Pipeline by Annovis Bio Inc, H2 2019

Down Syndrome – Pipeline by Avanti Biosciences Inc, H2 2019

Down Syndrome – Pipeline by Balance Therapeutics Inc, H2 2019

Down Syndrome – Pipeline by Eisai Co Ltd, H2 2019

Down Syndrome – Pipeline by Elixirgen Therapeutics LLC, H2 2019

Down Syndrome – Pipeline by F. Hoffmann-La Roche Ltd, H2 2019

Down Syndrome – Pipeline by KinoPharma Inc, H2 2019

Down Syndrome – Pipeline by ManRos Therapeutics, H2 2019

Down Syndrome – Pipeline by NeuroCircuit Therapeutics Inc, H2 2019

Down Syndrome – Pipeline by NeuroNascent Inc, H2 2019

Down Syndrome – Pipeline by San Biotechnology Co Ltd, H2 2019

Down Syndrome – Dormant Projects, H2 2019

Down Syndrome – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Down Syndrome, H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Number of Products by Top 10 Targets, H2 2019

Number of Products by Stage and Top 10 Targets, H2 2019

Number of Products by Top 10 Mechanism of Actions, H2 2019

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports